Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – C-o-group doai
Reexamination Certificate
1997-09-18
2001-09-25
Reamer, James H (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C-o-group doai
C514S724000, C514S739000, C514S548000, C514S623000
Reexamination Certificate
active
06294585
ABSTRACT:
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
Not Applicable
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to increasing the differentiation of mammalian neuronal cells for purposes of treating neurodegenerative diseases or nerve damage by administration of various compounds including alcohols, diols and/or triols and their analogues.
2. Description of Related Art
The compositions which are the subject of the present invention have been found to increase the melanin content of mammalian melanocytes, increase pigmentation in the epidermis of a mammal, and treat or prevent various skin and proliferative disorders. See U.S. application Ser. No. 60/026,577 filed Sep. 18, 1996; application Ser. No. 60/035,947 filed Jan. 21, 1997; application Ser. No. 60/036,863 filed Feb. 4, 1997, and application Ser. No. 60/048,597 filed Jun. 4, 1997. It has now been found that the present compositions may be used for treating neurodegenerative diseases or nerve damage.
SUMMARY OF THE INVENTION
The present invention provides a method for increasing the differentiation of mammalian neuronal cells, which comprises administering to a mammal in need of such increase an effective amount of one or more compounds having the following structure:
wherein
X
1
, X
2
, and X
3
are independently selected from a single bond; or a group containing from one atom to twenty atoms, at least one of which is carbon, nitrogen, oxygen or sulfur;
each of R
1
and R
2
is independently selected from hydrogen; halogen; or a group containing from one atom to twenty atoms, one of which is carbon, nitrogen, oxygen, or sulfur;
each of R
3
and R
4
is independently selected from hydrogen or an acyl or amino acyl group containing from one atom to twenty atoms, at least one of which is carbon, nitrogen, oxygen, or sulfur;
R
5
is a linear, branched or unbranched, cyclic, bicyclic or polycyclic group containing from one atom to fifty atoms, at least one of which is carbon, nitrogen, oxygen, or sulfur, and
each R
6
is independently selected from hydrogen; halogen; or a group containing from one atom to twenty atoms, one of which is carbon, nitrogen, oxygen, or sulfur; hydroxyl, hydroxymethyl, —(CH
2
)
n
OH, —(CH
2
)
n
OR
1
, —(CH
2
)
n
—CH(OH)—CHOH, —(CH
2
)
n
—CH(OH)—CH(OH)R
1
, —(CH
2
)
n
—CH(OH)—(CH
2
)
n
—CH
2
(OH), —(CH
2
)
n
—CH(OH)—(CH
2
)
n
—CH(OH)R
1
or —CH
2
OR
3
, wherein each n is independently an integer from 0-25;
and pharmaceutically acceptable salts thereof In another aspect, the present invention provides a composition for increasing the differentiation of mammalian neuronal cells, which comprises:
a) an effective amount of one or more compounds described above; and
b) a suitable carrier.
REFERENCES:
patent: 3956361 (1976-05-01), Stephen
patent: 4647585 (1987-03-01), Loots et al.
patent: 5130136 (1992-07-01), Shono et al.
patent: 5414019 (1995-05-01), Gould et al.
patent: 5587402 (1996-12-01), Gould et al.
patent: 5602184 (1997-02-01), Myers et al.
patent: 5747532 (1998-05-01), Lai
patent: 5990177 (1999-11-01), Brown
patent: 1 200 862 (1970-08-01), None
Muck Index, 10th Edn, #1708, 2896, 3744, 7756, 9522, 1983.*
Bradford, M. “A Rapid and Sensitive Method for the Quantitation of Mictogram Quantities of Protein Utilizing the Principle of Protein-Dye Binding,”Anal. Biochem., 1967, 72:248-254.
Buchbauer et al., “Norbornanaverbindungen in der pharmazeutischen Forschung,”Pharmazie, 1991, 46(Teil 1):88-97, and 46 (Teil 2):116-170.
Buchbauer et al., “Syntheses in the isocamphane series,”Chemical Abstracts, vol. 95, NO. 115756e, 1981.
Chijiwa et al., “Inhibition of Forskolin-induced Neurite Outgrowth and Protein Phosphorylation by a Newly Synthesized Selective Inhibitor of Cyclic AMP-dependent Protein Kinases, N-[2- (p-Bromocinnamyl-amino) ethyl] -5-isoquinolinesulfonamide (H-89), of PC12D Phenochromocytoma Cells,”J. Biol. Chem., 1990, 265:5267-5272.
Crowell et al., “Chemoprevention of mammary carcinogenesis by hydroxylated derivatives of d-limonene,”Carcinogenesis, 1992, 13:1261-1264.
Crowell et al., “Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation,”Biochemical Pharmacology,1994, 47:1405-1415.
Durham et al., “Use of tissue culture models to study environmental-genetic interactions relevant to neurodegenerative diseases,”Clin. Exp. Pharmacol. Physiol., 1995, 22:366-67.
Greene et al., “Methodologies for the culture and experimental use of the rat PC12 rat pheochtomocytoma cells line,”Culturing Nerve Cells, The MIT Press, Cambridge, Massachusetts, 1991, pp. 207-226.
Groner et al., “Cell damage by excess CuZnSOD and Down's Syndrome,”Biomed. Pharmacother., 1994, 48:231-240.
Haag et al., “Mammary carcinoma regression induced by perillyl alcohol, a hydroxilated analog of limonene,”Cancer Chemotherapy and Pharmacology, 1994, 34:477-483.
Haase et al., “Gene therapy of murine motor neuron disease using adenoviral vectors for neurothrophic factors,”Nature Medicine, 1997, 3:429-436.
He et al., “Isoprenoids Suppress the Growth of Murine B16 Melanomas In Vitro and In Vivo,”J. Nutr.,1997, 127:668-674.
Ishida et al., “Biotransformation of terpenoids in mammals,”Chemical Abstracts, vol. 93, #89860W, 1980.
Jager et al., “Investigation of cytotoxic effects of 8 norbornane derivatives on 4 human cancer cell lines using the MTT assay,”Pharmazie,1995, 50:619-621.
Kamikubo et al., “Preparation of (+)—tricycloen-3-one and its conversion into (+) -epi-&bgr;-santalene,”Chemical Abstracts, vol. 122, No. 265669u, 1994.
Karg et al., “Stimulation of Tyrosinase by Dihydroxy Phenyl Derivatives,”Acta Derm. Venereol., 1989, 69:521-524.
Koval′ skaya et al., “Determination of the spatial structure of mono- and bicyclic terpene derivatives on the base of nuclear magnetic resonance spectroscopy data,”Chemical Abstracts, vol. 125, No. 276201y, 1996.
Kozlov et al., “Camphene in the synthesis oxygen- and nitrogen-containing bicyclic derivatives,”Chemical Abstracts, vol. 120, No. 77469p, 1994.
Laukharanta et al., “Changes in Three-Dimensional Structure of Cultured S91 Mouse Melanoma Cells Associated with Growth Inhibition and Induction of Melanogenesis by Retinoids,”Arch. Dermatol. Res., 1985, 277:147-150.
Merkel, D. “10-Methylenetricyclene,”Chemical Abstracts, vol. 66, No. 94723a, 1967.
Michel et al., “Morphological and Molecular Characterization of the Response of Differentiated PC12 Cells to Calcium Stress,”Europ. J. Neurosci. Assoc., 1994, 6:577-586.
Miftakhov et al., “Prostanoids,”Chemical Abstracts, vol. 121, No. 157329d, 1994.
Nagatsu et al., “A Rapid and Simple Radioassay for Tyrosine Hydroxylase Activity,”Anal. Biochem.,1969, 9:122-126.
Ribeiro et al., “The Hydroxylation of Phenylalanine and Tyrosine by Tyrosine Hydroxylase from Cultured Pheochromocytoma Cells,”J. Biol. Chem.,1991, 16207-16211.
Riederer et al., “Recent Advances in Pharmacological Therapy of Parkinson's Disease,”Adv. Neurol.,1993, 60:626-635.
Romero et al., “Retinoic acid as modulator of UVB-induced melanocyte differentation,”J. Cell Sci.,1994, 107:1095-1103.
Rukenstein et al., “Multiple Agents Rescue PC12 Cells from Serum-free Cell Death by Translation- and Transcrption-independent Mechanisms,”J. Neurosci.,1991, 11:2552-2563.
Russin et al., “Inhibition of rat mammary carcinogenesis by monoterpenoids,”Carcinogenesis,1989, 10:2161-2164.
Sandrock et al., “Identification of a peripheral nerve neurite grwoth-promoting activity by development and use of an in vitro bioassay,”Proc. Natl. Acad. Sci. U.S.A.,1987, 84:6934-6938.
Shen et al., “Complement-mediated neurotoxcity is regulated by homologus restritction,”Brain Res.,1995, 671:282-292.
Shi et al., “Induction of differentiation in neuro-2A cells by the monoterpene perillyl alcohol,”Cancer Letters 95, 1995, 1-6.
Shoff et al., “Concentration-dependent Increase of Murine P388 and B16 Population Doubling time by the Acyclic Monoterpene Geraniol,”Cancer Research,1991, 41:37-42.
Steiner et al. “Neurotrophic actions of nonimmuno-suppressive analogues of immunosuppressive drugs FK50
Applied Genetics Incorporated Dermatics
Klee Maurice M.
Reamer James H
LandOfFree
Treatment of neurodegenerative diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of neurodegenerative diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of neurodegenerative diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2483816